Clinical trials: Severe Respiratory Distress Syndrome
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Respiratory Distress Syndrome (ARDS)
Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS
Acute respiratory distress syndrome (ARDS) poses a major threat to human health. Despite extracorporeal membrane oxygenation (ECMO) support, mortality among patients with ARDS remains high due to severe complications and…
- Trial name
- NCT07726940
- Where
- 39 sites in China
- Volunteers
- 1,776 people
- Sponsor
- Southeast University, China
Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure (ARF)
Right Heart Injury Monitoring on ECMO
This study aims to find out whether it is practical to introduce a consistent monitoring approach to the right side of the heart in patients supported with VV-ECMO.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure (ARF), Right Heart Failure, Unspecified
- Trial name
- RHIME (NCT07880730)
- Testing
- Transthoracic echocardiogram, High sensitivity troponin, N-terminal pro-B-type natriuretic peptide
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Intensive Care Units, ARDS, Human
Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections
Severe Covid-19 (Coronavirus Disease 2019) infections generate major but inappropriate production of cytokines and, in some cases, generate anti-IFN (Interferon) auto-antibodies, inducing acute respiratory distress syndrom…
- Conditions
- Intensive Care Units, ARDS, Human, Covid19
- Trial name
- CovidEP (NCT04751643)
- Testing
- Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3), Usual treatments in intensive care unit according to the current state of knowledge
- Where
- 8 sites in France
- Volunteers
- 21 people
- Sponsor
- Hospices Civils de Lyon
Acute Respiratory Distress Syndrome, Pneumonia
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
- Conditions
- Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
- Trial name
- iGRASP (NCT02601365)
- Testing
- Sargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
- Sponsor
- Milton S. Hershey Medical Center
ARDS (Acute Respiratory Distress Syndrome), VV ECMO
Trial of Total Lung Protective Ventilation in Adult VV-ECMO Patients With Severe ARDS
The purpose of this study is to find a better way to protect the lungs of patients with Acute Respiratory Distress Syndrome (ARDS) who are being treated with a mechanical ventilator in addition to an extracorporeal membrane…
- Trial name
- PROTECT-ARDS (NCT07790133)
- Testing
- Mechanical Power Targeted Ventilation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Virginia
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
SARS-CoV 2, COVID
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-2 (NCT04360096)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Where
- 13 sites in United States
- Volunteers
- 144 people
- Sponsor
- APR Applied Pharma Research s.a.
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Covid19
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or…
- Trial name
- NCT04922957
- Testing
- ALLOCETRA-OTS
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Enlivex Therapeutics Ltd.
COVID, Corona Virus Infection
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease.
- Conditions
- COVID, Corona Virus Infection, Acute Lung Injury, Ischemia Limb
- Trial name
- NCT04659460
- Testing
- Remote Ischemic Conditioning
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
- Trial name
- SONIC-19 (NCT04725084)
- Testing
- Use of High Flow Nasal Cannula alone, Use of Non-invasive Ventilation, Use of Continuous Positive Airway Pressure
- Where
- 4 sites in France
- Volunteers
- 355 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome
EVLWI Exhibits Pulmonary and Systemic Permeability in Sepsis Related ALI/ARDS
To investigate the possible mechanisms of pulmonary and systemic permeability change including cytokine, extravascular lung water index (EVLWI), and oxygenation parameters in patients with sepsis related acute lung injury…
- Trial name
- NCT01694147
- Testing
- PiCCO monitoring system
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Mesenchymal Stromal Cells, Remestemcel-L
MSCs in COVID-19 ARDS
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation.
- Conditions
- Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
- Trial name
- NCT04371393
- Testing
- Remestemcel-L
- Where
- 21 sites in United States
- Volunteers
- 223 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Acute Respiratory Distress Syndrome / Severe ARDS, Invasive Mechanical Ventilation
Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients
The acute respiratory distress syndrome (ARDS) is common condition in critical ill patients affecting 7.2 people / 100,000 population / year and more than 7% of patients with invasive mechanical ventilation for more than 24…
- Conditions
- Severe Acute Respiratory Distress Syndrome / Severe ARDS, Invasive Mechanical Ventilation, Individualized PEEP Treatment Strategy
- Trial name
- ENCODE (NCT02617914)
- Testing
- individualized PEEP treatment, Invasive mechanical ventilation, ECMO,
- Sponsor
- RWTH Aachen University
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
ARDS (Moderate or Severe)
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS…
- Trial name
- NCT07490925
- Testing
- Transpulmonary pressure guided mechanical ventilation strategy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Chao Yang Hospital
SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial.
- Conditions
- SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Mutation
- Trial name
- SEVARVIR (NCT05162508)
- Testing
- Nasopharyngeal swab
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris